AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
AstraZeneca’s new U.S. spending also leaves in doubt the pharmaceutical company’s plans to invest in a vaccine site in ...
The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...
Hope is on the horizon for needle-phobic patients as Griffith University researchers have created a new influenza vaccine ...
On the heels of releasing its latest financial statement, Vancouver-based biotechnology company Absci announced it has met its first milestone in its collaboration with pharmaceutical giant AstraZenec ...
Investor's Business Daily on MSN16h
AstraZeneca Stock Dives As China's Criminal Probe Rattles Its Third-Quarter BeatAstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, but AstraZeneca stock slipped amid a criminal probe in China.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback